骨髓纤维化患者异基因造血干细胞移植前脾切除术:法国全国性研究
该研究基于法国骨髓移植登记组2008至2017年启动无关供者搜索的530例骨髓纤维化患者,采用四状态多状态模型分析移植前脾切除术与allo-HCT发生率的关系。中位随访6年,脾切除术后前4个月allo-HCT风险比为7.2(95%CI 5.1-10.3),此后为1.18(0.69-2.03);脾切除与死亡的风险比为1.58(0.79-3.14)。结果提示脾切除术并不妨碍骨髓纤维化患者接受allo-HCT。
要点
- 移植前脾切除术与allo-HCT风险在前4个月显著升高(HR 7.2),之后无显著关联。
- 脾切除术与死亡风险无显著增加(HR 1.58,95%CI 0.79-3.14)。
- 脾切除术不应被视为骨髓纤维化患者allo-HCT的禁忌。
核心结论
- 脾切除术不排除骨髓纤维化患者后续接受allo-HCT的可能性。
研究设计与样本
- 回顾性研究,纳入2008年1月1日至2017年1月1日经法国骨髓移植登记组启动无关供者搜索的530例骨髓纤维化患者,来自57个中心。
- 采用四状态多状态模型(RFGM登记、脾切除术、移植前死亡、allo-HCT)评估脾切除术与allo-HCT发生率的关联。
主要发现
- 中位随访6年,共发生81例脾切除术、99例移植前死亡(90例未脾切除,9例脾切除后)和333例allo-HCT(268例未脾切除,65例脾切除后)。
- 双变量分析中,脾切除术与allo-HCT关联的风险比在最初4个月为7.2(95%CI 5.1-10.3),此后为1.18(95%CI 0.69-2.03)。
- 脾切除术与死亡关联的风险比为1.58(95%CI 0.79-3.14)。
临床怎么用
- 骨髓纤维化患者移植前脾切除术不应被视为allo-HCT的禁忌,可考虑后续移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The value of pretransplant splenectomy in patients with myelofibrosis (MF) is subject to debate, since the procedure may preclude subsequent allogeneic hematopoietic cell transplantation (allo-HCT). To determine the impact of pretransplant splenectomy on the incidence of allo-HCT, we conducted a comprehensive retrospective study of all patients with MF for whom an unrelated donor search had been initiated via the French bone marrow transplantation registry (RFGM) between 1 January 2008 and 1 January 2017. Additional data were collected from the patients' medical files and a database held by the French-Language Society for Bone Marrow Transplantation and Cell Therapy (SFGM-TC). We used a multistate model with four states ("RFGM registration"; "splenectomy"; "death before allo-HCT", and "allo-HCT") to evaluate the association between splenectomy and the incidence of allo-HCT. The study included 530 patients from 57 centers. With a median follow-up time of 6 years, we observed 81 splenectomies, 99 deaths before allo-HCT (90 without splenectomy and nine after), and 333 allo-HCTs (268 without splenectomy and 65 after). In a bivariable analysis, the hazard ratio [95% confidence interval (CI)] for the association of splenectomy with allo-HCT was 7.2 [5.1-10.3] in the first 4 months and 1.18 [0.69-2.03] thereafter. The hazard ratio [95% CI] for death associated with splenectomy was 1.58 [0.79-3.14]. These reassuring results suggest that splenectomy does not preclude allo-HCT in patients with MF.
引用
- Bossard JB, Beuscart JB, Robin M, et al. Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. Am J Hematol. 2020. PMID: 33108024. doi:10.1002/ajh.26034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。